Technical Data
K1765-30
Kijanimicin (Antibiotic Sch 25663)
500ug
Biochemicals Storage: -20CShipping: Blue Ice
Kijanimicin is a tetronic acid related to saccharocarcin, chlorothricin, versipelostatin and tetrocarcin. Like the tetrocarcins, kijanimicin contains an unusual nitro-aminoglycoside. Kijanimicin is a potent antibacterial, antimalarial and antitumor activity. However, several members of this class have received considerable literature focus. Versipelostatin was shown to inhibit transcription from the promoter of GRP78, a gene that is activated as part of a stress signaling pathway under glucose deprivation resulting in unfolded protein response (UPR). The UPR-inhibitory action was seen only in conditions of glucose deprivation and caused selective and massive killing of the glucose-deprived cells. While tetrocarcin A appears to target the phosphatidylinositide-3'-kinase/Akt signaling pathway.

Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute by adding ethanol, methanol, DMF or DMSO. Aliquot and store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

CAS Number:
78798-08-0

Molecular Formula:
C67H100N2O24

Molecular Weight:
1317.5
Source: Actrinomadura sp.
Purity: ~99% by HPLC
Form: Supplied as a white solid.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Kijanimicin (Sch 25663), a novel antibiotic produced by Actinomadura kijaniata SCC1256. Waitz, J.A. et al., J. Antibiot., 1981, 34, 1101. 2. Antitumor activity of kijanimicin Bradner W. T. J. Antibiot. 1983, 36, 1078. 3. Effect on tumor cells of blocking survival response to glucose deprivation. Park H.R. J. Natl. Cancer. Inst. 2004, 96, 1300. 4. Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers. Nakajima H. Biochem Biophys Res Commun. 2007, 356, 260.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.